1 Development and Validation of a Metabolite Index for Obstructive

2

Sleep Apnea across Race/Ethnicities

3	Ying Zhang ¹ , D	Debby Ngo ² ,	Bing Yu ³ , N	leomi A. Shah ⁴	, Han Chen ^{3,5} ,	Alberto R.	Ramos ⁶ , Ph	yllis (С.
---	-----------------------------	--------------------------	--------------------------	----------------------------	-----------------------------	------------	-------------------------	---------	----

4 Zee⁷, Russell Tracy⁸, Peter Durda⁸, Robert Kaplan⁹, Martha L. Daviglus¹⁰, Stephen S.

5 Rich¹¹, Jerome I. Rotter¹², Jianwen Cai¹³, Clary Clish¹⁴, Robert Gerszten¹⁵, Bruce S.

6 Kristal^{16,17}, Sina A. Gharib¹⁸, Susan Redline¹⁷, Tamar Sofer^{16,19,*}

⁷ ¹Department of Medicine, Division of Sleep Medicine and Circadian Disorders, Brigham and

8 Women's Hospital, Boston, MA, 02115, ²Cardiovascular Institute, Division of Pulmonary, Critical

9 Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA, 02215, ³Human

10 Genetics Center, Department of Epidemiology, Human Genetics and Environmental Sciences,

11 School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX,

12 77030, ⁴Department of Medicine, Albert Einstein College of Medicine, New York, NY,

13 10029, ⁵Center for Precision Health, School of Biomedical Informatics, The University of Texas

14 Health Science Center at Houston, Houston, TX, 77030, ⁶Department of Neurology, Sleep

15 Medicine Program, University of Miami Miller School of Medicine, Miami, FL,

16 33136, ⁷Department of Neurology, Division of Sleep Medicine, Northwestern University,

17 Chicago, IL, 60611, ⁸Department of Pathology Laboratory Medicine, Larner College of Medicine,

18 University of Vermont, Burlington, VT, 05405, ⁹Department of Epidemiology & Population

- 19 Health, Albert Einstein College of Medicine, Bronx, NY, 10461, ¹⁰Department of Preventive
- 20 Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 60612, ¹¹Center
- 21 for Public Health Genomics, University of Virginia, Charlottesville, VA, 22908, ¹²Department of

22	Pediatrics, The Institute for Translational Genomics and Population Sciences, The Lundquist
23	Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA,
24	90502, ¹³ Department of Biostatistics, Collaborative Studies Coordinating Center, University of
25	North Carolina at Chapel Hill, Chapel Hill, NC, 27599, ¹⁴ Metabolite Profiling Platform, Broad
26	Institute of MIT and Harvard, Cambridge, MA, 02142, ¹⁵ Cardiovascular Research Center,
27	Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02115, ¹⁶ Department of
28	Medicine, Sleep and Circadian Disorders, Harvard Medical School, Boston, MA,
29	02115, ¹⁷ Department of Medicine, Division of Sleep Medicine and Circadian Disorders, Brigham
30	and Women's Hospital and Harvard Medical School, Boston, MA, 02115, ¹⁸ Department of
31	Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington,
32	Seattle, WA, 98195, ¹⁹ Department of Biostatistics, Harvard T.H. Chan School of Public Health,
33	Boston, MA, 02115
34	
35	*Corresponding Author
36	Email: <u>tsofer@bwh.harvard.edu</u> (TS)
37	
38	

39 Author's contributions

- 40 Conception: D.N, T.S., Y.Z.; MESA Metabolomics measurement and study design: D.N., R.G.,
- 41 C.C., S.S.R., J.I.R.; HCHS/SOL metabolomics measurement and study design: B.Y.; Sleep data

- 42 collection: S.R.; Data analysis: Y.Z., T.S.; MESA data collection: S.S.R., J.I.R.; HCHS/SOL data
- 43 collection: P.C.Z., R.K., M.D., J.C.; Results interpretation and critical review of manuscript:
- 44 Everyone.

45 Abstract

46

47	Background: Obstructive sleep apnea (OSA) is a common disorder characterized by recurrent
48	episodes of upper airway obstruction during sleep resulting in oxygen desaturation and sleep
49	fragmentation, and associated with increased risk of adverse health outcomes. Metabolites are
50	being increasingly used for biomarker discovery and evaluation of disease processes and
51	progression. Studying metabolomic associations with OSA in a diverse community-based cohort
52	may provide insights into the pathophysiology of OSA. We aimed to develop and replicate a
53	metabolite index for OSA and identify individual metabolites associated with OSA.
54	Methods and Findings: We studied 219 metabolites and their associations with the apnea
55	hypopnea index (AHI) and with moderate-severe OSA (AHI \geqslant 15) in the Hispanic Community
56	Health Study/Study of Latinos (HCHS/SOL) (n=3507) using two methods: (1) association analysis
57	of individual metabolites, and (2) least absolute shrinkage and selection operator (LASSO)
58	regression to identify a subset of metabolites jointly associated with OSA, and develop a
59	metabolite index for OSA. Results were validated in the Multi-Ethnic Study of Atherosclerosis
60	(MESA) (n=475). When assessing the associations with individual metabolites, we identified
61	seven metabolites significantly positively associated with OSA in HCHS/SOL (FDR p<0.05), of
62	which four associations - glutamate, oleoyl-linoleoyl-glycerol (18:1/18:2), linoleoyl-linoleoyl-
63	glycerol (18:2/18:2) and phenylalanine, replicated in MESA (one sided- p <0.05). The OSA
64	metabolite index, composed of 14 metabolites, was associated with 50% increase of risk for
65	moderate-severe OSA (OR=1.50 [95% CI: 1.21-1.85] per 1 SD of OSA metabolite index, p<.001)

- in HCHS/SOL and 44% increased risk (OR=1.55 [95% CI: 1.10-2.20] per 1 SD of OSA metabolite
- 67 index, p=0.013) in MESA, both adjusted for demographics, lifestyle, and comorbidities. Similar
- 68 albeit less significant associations were observed for AHI.
- 69 **Conclusions:** We developed a metabolite index that replicated in an independent multi-ethnic
- 70 dataset, demonstrating the robustness of metabolomic-based OSA index to population
- 71 heterogeneity. Replicated metabolite associations may provide insights into OSA-related
- 72 molecular and metabolic mechanisms.

74 Introduction

75	Obstructive sleep apnea (OSA) is a common disorder characterized by recurrent
76	episodes of upper airway obstruction during sleep resulting in oxygen desaturation and sleep
77	fragmentation (1). While highly prevalent in the population (2), OSA is severely under-
78	diagnosed (3), especially in women (4). For example, only 1.3% of participants in the Hispanic
79	Community Health Study/Study of Latinos (HCHS/SOL) and 7-15% of participants in the Multi-
80	Ethnic Study of Atherosclerosis (MESA) reported a previous OSA diagnosis; in MESA,
81	underdiagnosis was highest among race/ethnic minorities (5,6). The pathophysiology
82	underlying OSA is multifaceted, which includes obesity, craniofacial structure, upper airway
83	neuronal control, ventilatory control, and inflammation, among others (7). OSA is also
84	associated with increased risk of adverse health outcomes, including hypertension,
85	cardiovascular disease, diabetes, and early mortality (8–11).
86	
87	Metabolomics is the study of small biochemical compounds at large scales (12). As a growing
88	number of large metabolomics datasets become available, metabolites are being increasingly
89	leveraged for biomarker discovery and evaluation of disease processes and progression (13,14).
90	In particular, studying metabolite associations with OSA may improve our understanding of the
91	pathophysiology of OSA. However, research in this area has been limited by the relatively small
92	number of participants that have undergone both overnight sleep studies and metabolomic
93	profiling, the lack of representativeness of the study subjects selected solely in clinical

94 encounters, and the limited metabolite panels used by many targeted metabolomics platforms95 (15,16).

96	Here, we study metabolite associations with OSA in the HCHS/SOL, one of the largest multi-
97	center cohorts with diverse participants from a rapidly growing minority group in the US:
98	Hispanics/Latinos. We then test these associations for replication in MESA, a multi-ethnic
99	community-based cohort. Our study follows the design described in Figure 1. First, we study
100	associations of individual metabolites with a measure of moderate to severe OSA, defined by
101	the apnea hypopnea index AHI \geqslant 15, as well as by associations with continuously measured
102	AHI. Next, we develop a metabolite index for OSA by aggregating together multiple metabolites
103	as a potential biomarker for OSA. We then validate its association with OSA in MESA. This
104	process is repeated for a continuous measure of OSA severity, the AHI. Because OSA has
105	different characteristics across sexes (17), in secondary analyses we additionally studied sex-
106	specific metabolite indices.



Figure 1: Study design flow chart.

Definition of abbreviations: LASSO = least absolute shrinkage and selection operator, HCHS/SOL= the Hispanic Community Health Study/Study of Latinos, MESA= the Multi-Ethnic Study of Atherosclerosis.

108

109 Methods

- 110 The Hispanic Community Health Study/Study of Latinos
- 111 The HCHS/SOL is a community-based cohort study of 16,415 self-identified Hispanic/Latino
- 112 persons from diverse Hispanic/Latino backgrounds (Mexicans, Puerto Ricans, Cubans, Central
- 113 Americans, Dominicans, and South Americans) (18). Participants 18–74 years of age at their

114	baseline examination were recruited through a stratified multistage area probability sample
115	design from four communities: San Diego, California; Chicago, Illinois; The Bronx, New York; and
116	Miami, Florida. The baseline examinations occurred in June 2008–July 2011 and included
117	assessment of OSA using a validated Type 3 home sleep apnea test (ARES Unicorder 5.2; B-
118	Alert, Carlsbad, CA) that measured nasal air-flow, position, snoring, heart rate and
119	oxyhemoglobin saturation (19) as previously described (5) in 14,440 individuals. The current
120	cross-sectional analysis included 3,507 of these participants who also had blood assessed for
121	metabolomic measures. Our primary analysis focused on a metabolomics-based biomarker for
122	moderate or severe OSA defined as AHI \geq 15, with events defined as apneas or hypopneas with
123	at least 50% cannula flow reduction for a minimum duration of 10 seconds, with \geqslant 3% oxygen
124	desaturation. The sleep study was conducted within the week following the baseline exam in
125	which blood was collected and used for metabolite quantification. The study was approved by
126	Institutional Review Boards at each field center where all participants provided written consent,
127	and by the study's Reading and Data Coordinating Centers.

128

129 HCHS/SOL Metabolomic Profiling

Fasting blood samples were collected at the baseline examination. Of all HCHS/SOL participants
from the baseline examination who also had genetic data, 3,968 individuals were selected at
random for metabolomics assessment. The samples were processed, and serum was stored at
-70°C since collection. The metabolomic profiling was conducted at Metabolon (Durham, NC)
with Discovery HD4 platform in 2017. Serum metabolites were quantified with untargeted,
liquid chromatography-mass spectrometry (LC-MS)-based quantification protocol (20).-The

136 platform captured a total of 1,136 metabolites, including 782 known and 354 unknown

- 137 (unidentified) metabolites.
- 138

139 The Multi-Ethnic Study of Atherosclerosis

140 MESA is a cohort study designed to study risk factors for clinical and subclinical cardiovascular

141 diseases in four racial/ ethnic groups (21). The study began in July 2000 and recruited 6,814

adults free of clinical CVD and aged 45–84 years from 6 centers: Baltimore, MD; Chicago, IL; Los

- 143 Angeles, CA; New York, NY; Saint Paul, MN; and Winston-Salem, NC. Participants were
- 144 continued to be studied through subsequent follow-up exams. Of the 4,077 participants who

attended Exam 5 (2010-2012), 2,261 participated in the MESA Sleep ancillary study (2010-

146 2013). As reported before (6), participants in the Sleep Exam were generally similar to non-

147 participants. OSA was assessed with Type II in-home polysomnography. AHI was defined as the

total number of apnea and hypopneas with at least 30% reduction in the nasal flow signal and

149 with \geq 3% oxygen desaturation per hour of sleep. The median time interval between Exam 5

150 fasting plasma sample collection and MESA Sleep was 301 days (range 0–1,024 days).

151 Metabolomic data was collected on 1,000 randomly selected participants from Exam 5. Of

- these, 475 participants also had sleep measures and are included in this analysis. Local
- institutional review boards at all the participating institutions approved study protocols, and all

154 participants gave written informed consent.

156 MESA Metabolomic Profiling

Metabolite profiling was performed using liquid chromatography tandem mass spectrometry 157 158 (LC-MS). Positive ion mode profiling of water-soluble metabolites and lipids was performed 159 using LC-MS systems comprised of Nexera X2 U-HPLC (Shimadzu Corp.; Marlborough, MA) units coupled to a Q Exactive mass spectrometer (Thermo Fisher Scientific; Waltham, MA). Polar 160 metabolites were analyzed using hydrophilic interaction liquid chromatography (HILIC) and 161 lipids were analyzed separately using reversed phase C8 chromatography as described in detail 162 previously (22). Raw data were processed using TraceFinder 3.1 (Thermo Fisher Scientific; 163 164 Waltham, MA) and Progenesis QI (Nonlinear Dynamics; Newcastle upon Tyne, UK). To measure organic acids and other intermediary metabolites in negative ionization mode, chromatography 165 166 was performed using an Agilent 1290 infinity LC system equipped with a Waters XBridge Amide column, coupled to an Agilent 6490 triple quadrupole mass spectrometer. Metabolite 167 transitions were assayed using a dynamic multiple reaction monitoring system. LC-MS data 168 were analyzed with Agilent Masshunter QQQ Quantitative analysis software. Isotope labeled 169 internal standards were monitored in each sample to ensure proper MS sensitivity for quality 170 control. Pooled plasma samples were interspersed at intervals of 10 participant samples for 171 standardization of drift over time and between batches. Additionally, separate pooled plasma 172 173 was interspersed at every 20 injections to determine coefficient of variation for each metabolite over the run. Peaks were manually reviewed in a blinded fashion to assess quality. 174 175 For each method, metabolite identities were confirmed using authentic reference standards or reference samples. Metabolites with poor peak quality and coefficients of variation greater 176 than 30% averaged across batches were removed from analysis. 177

178

179	Quality control of metabolites in HCHS/SOL and MESA
180	Missing metabolite values were addressed as described in Supplemental Figure 1. In our
181	discovery sample (HCHS/SOL), we excluded individuals with more than 25% missing metabolite
182	levels, and metabolites with missing values for 75% or more individuals. For metabolites with
183	more than 25% and less than 75% missing values, values were dichotomized as "observed" and
184	"unobserved". For metabolites with less than 25% missing values, we imputed the missing
185	values using the minimum observed value of the metabolite in the sample, under the
186	assumption that metabolites were not observed due to a technical detection limit.
187	
188	Because our study design includes validation analysis, we focused on metabolites available in
189	both HCHS/SOL and MESA. Before any quality control (QC) methods were applied, 231
190	HCHS/SOL metabolites were mapped to 294 metabolites in MESA. The mapping of MESA to
191	HCHS/SOL metabolites as well as to RefMet ID was done at Clish Lab. MESA had multiple
192	metabolites matched to a single HCHS/SOL metabolite in multiple instances because the same
193	metabolite was measured via more than one platform used by MESA. In some cases, a single
194	metabolite appears as two highly correlated ion features in the same MESA platform (e.g.,
195	some neutral lipids were measured as both sodium and ammonium adducts). Therefore, a single
196	feature was mapped to the metabolite in HCHS/SOL while the redundant features were dropped
197	according to the following principles: features with redundant ions were excluded; features with
198	lower missingness and lower skewness were prioritized. After removing 60 such redundant
199	features in MESA and applied QC methods based on the missingness in HCHS/SOL, 219

HCHS/SOL metabolites were mapped to 219 metabolites in MESA. Table S1 provides the list of
the 294 initially matched metabolites cross-referenced by RefMet ID and metabolite
annotations including HMDB IDs provided by Metabolon, along with details regarding
metabolite-specific QC resulting in the final list of one-to-one matched metabolites. The serum
concentration values of the matched metabolites that were treated as continuous were ranknormalized.

Because MESA was a validation study, we only evaluated metabolites that were identified in the association analysis in HCHS/SOL. The missing data for these metabolites were always <25%, so we treated these as continuous variables and imputed missing values with the minimum observed value in the MESA sample.

211

212 Statistical analysis

Association analyses were based on three conceptual regression models: Model 1 (i.e., primary 213 model) adjusted for demographic variables – age, sex, study center, Hispanic background 214 (Mexicans, Puerto Ricans, Cubans, Central Americans, Dominicans, and South Americans and 215 216 other/multi), and body mass index (BMI) in HCHS/SOL; age, sex, study site (two sites with low sample sizes were combined), race (White versus "Non-White", which consists of Hispanic, Black 217 and Chinese Americans), and BMI in MESA. Model 2 (i.e., lifestyle model) adjusted for 218 demographic and lifestyle variables - alcohol use, cigarette use, total physical activity (MET-219 min/day), and diet (Alternative Healthy Eating Index 2010) in HCHS/SOL; alcohol use and 220 cigarette use in MESA. Model 3 (i.e., lifestyle and comorbidity model) adjusted for demographic, 221

lifestyle and comorbidity variables - indicators for diabetes, hypertension, fasting insulin, fasting
glucose, HOMA-IR, HDL, LDL, total cholesterol, triglycerides, systolic blood pressure and diastolic
blood pressure in HCHS/SOL; hypertension, fasting glucose, HDL, LDL, cholesterol, triglycerides,
systolic blood pressure and diastolic blood pressure in MESA. All models used the same set of
individuals with complete set of sleep and covariate measures.

227

228	Association analysis between individual metabolites and OSA and AHI
229	We tested the association of each of 219 metabolites (both continuous and dichotomized
230	metabolites) with moderate-severe OSA and AHI in the HCHS/SOL. Each metabolite was the
231	exposure in either linear or logistic regression (depending on the outcome) for each model. We
232	accounted for the HCHS/SOL study design (sampling and clustering) and obtained
233	representative effect estimates using survey regression implemented in the R survey package
234	(4.0) (23). We controlled the false discovery rate (FDR) using the Benjamini-Hochberg
235	procedure (24) and determined significant associations as those with FDR p-value<0.05. In the
236	replication analysis, we tested the associations of these metabolites with OSA in logistic
237	regression and with AHI in linear regression in MESA in models 1-3. We computed one-sided p-
238	values guided by the estimated direction of associations in the HCHS/SOL (25), and determined
239	replication if the one-sided p-value was <0.05.

241 LASSO regression for constructing metabolite indices

242	We applied a LASSO logistic regression with moderate to severe OSA versus no or mild OSA (for
243	brevity "OSA versus no OSA"), and linear regression with AHI – log transformed as log(AHI+1),
244	adjusted for the covariates in Model 1 in HCHS/SOL. We included 209 continuous metabolites
245	(not including the 10 dichotomized metabolites). We selected the LASSO tuning parameter by
246	minimizing the misclassification error for OSA (assuming probability of 0.5 is the cutoff for
247	"predicting" OSA), and the prediction error for AHI, in a 10-fold cross-validation. Metabolite
248	indices were calculated as a weighted sum of the (normalized) metabolite serum
249	concentrations, with weights being the metabolite coefficients from the LASSO regression.
250	
251	To validate the metabolite index association with OSA/AHI, we constructed the indices in MESA
252	using the weights from the LASSO regression conducted in HCHS/SOL, then assessed their
253	associations with the corresponding sleep traits (i.e., OSA, AHI) in model 1-3. In the secondary
254	analyses we assessed potential sex differences via: (1) sex-stratified association analysis for sex-
255	specific metabolite indices (constructed based on sex-stratified LASSO), as well as (2) sex-
256	stratified association analysis for metabolite indices constructed based on combined sexes. We
257	also assessed the associations between metabolite indices quartiles and the corresponding
258	sleep traits.

259

All analyses were done in R 3.6.3. The glmnet package (3.0)(26) in R was used for the LASSO
logistic regression.

262

263 **Results**

- 264 Participant characteristics
- **Table 1** characterizes the HCHS/SOL analytic sample and target population. The HCHS/SOL
- cohort included 3,507 participants, with a mean age of 41.72 years (SD =15.4), of whom 50.7%
- were female and 10.2% were classified with moderate or severe OSA (AHI \ge 15). Participants
- with OSA were more likely to be male, had a higher BMI, and were less likely to be never
- smokers compared to those without OSA. Individuals with OSA were also more likely to have
- co-morbidities: 60% had hypertension and 34.3% had diabetes, compared to 27.8%
- 271 hypertension and 16.9% diabetes in those without OSA. **S2 Table** characterizes the 475 MESA
- 272 participants with metabolomics, sleep, and required measured covariates from the validation
- dataset. MESA participants were older (mean 68.45 years, SD=9.33), with a higher proportion of
- females (56.2%). Reflecting their older age, more MESA participants had moderate or severe
- 275 OSA (46.7%) compared to HCHS/SOL.

277	Table 1. Characteristic	s of Hispanics/Latinos	represented by	<pre>the HCHS/SOL study population</pre>
				· · · · · · · · ·

	Stratified	d by sex	Stratified by	by OSA status Total	
Mean (SD)	Female	Male	AHI<15	AHI≥15	
n	2011	1496	3122	385	3507
Age	42.22 (15.12)	41.20 (14.94)	40.29 (14.60)	54.20 (12.91)	41.72 (15.04)
Gender = Male (%)	0 (0.0)	1496 (100.0)	1252 (40.1)	244 (63.4)	1496 (49.3)
Latino background					
(%)					
Dominican	220 (10.9)	121 (8.2)	301 (9.6)	40 (10.4)	341 (10.7)
Central American	205 (10.2)	136 (5.7)	304 (9.7)	37 (9.6)	341 (6.4)

Mexican 795 (39.5) 558 (35.7) 1221 (39.1) 132 (34.3) 1353 (36.7) Puerto Rican 334 (16.6) 267 (17.8) 535 (17.1) 66 (17.1) 601 (16.4) South American 121 (6.0) 86 (3.7) 187 (6.0) 20 (5.2) 207 (4.5) Multi 57 (2.8) 49 (4.3) 95 (3.0) 11 (2.9) 106 (3.8) Alcohol drinking status (%) 512 (25.5) 116 (8.1) 568 (18.2) 60 (15.6) 628 (16.3) former 698 (34.7) 447 (27.7) 1000 (32.0) 145 (37.7) 1145 (29.5) current 800 (39.8) 933 (64.1) 1553 (49.8) 180 (46.8) 1733 (54.2) Smoking status (%) 2092 (61.5) 1906 (61.1) 186 (48.3) 2092 (61.5)
Puerto Rican 334 (16.6) 267 (17.8) 535 (17.1) 66 (17.1) 601 (16.4) South American 121 (6.0) 86 (3.7) 187 (6.0) 20 (5.2) 207 (4.5) Multi 57 (2.8) 49 (4.3) 95 (3.0) 11 (2.9) 106 (3.8) Alcohol drinking status (%) 60 (15.6) 628 (16.3) former 512 (25.5) 116 (8.1) 568 (18.2) 60 (15.6) 628 (16.3) former 698 (34.7) 447 (27.7) 1000 (32.0) 145 (37.7) 1145 (29.5) current 800 (39.8) 933 (64.1) 1553 (49.8) 180 (46.8) 1733 (54.2) Smoking status (%) 1906 (61.1) 186 (48.3) 2092 (61.5)
South American 121 (6.0) 86 (3.7) 187 (6.0) 20 (5.2) 207 (4.5) Multi 57 (2.8) 49 (4.3) 95 (3.0) 11 (2.9) 106 (3.8) Alcohol drinking status (%) never 512 (25.5) 116 (8.1) 568 (18.2) 60 (15.6) 628 (16.3) former 698 (34.7) 447 (27.7) 1000 (32.0) 145 (37.7) 1145 (29.5) current 800 (39.8) 933 (64.1) 1553 (49.8) 180 (46.8) 1733 (54.2) Smoking status (%) 1906 (61.1) 186 (48.3) 2092 (61.5)
Multi 57 (2.8) 49 (4.3) 95 (3.0) 11 (2.9) 106 (3.8) Alcohol drinking status (%)
Alcohol drinking status (%)
status (%) never 512 (25.5) 116 (8.1) 568 (18.2) 60 (15.6) 628 (16.3) former 698 (34.7) 447 (27.7) 1000 (32.0) 145 (37.7) 1145 (29.5) current 800 (39.8) 933 (64.1) 1553 (49.8) 180 (46.8) 1733 (54.2) Smoking status (%) 1 1906 (61.1) 186 (48.3) 2092 (61.5)
never 512 (25.5) 116 (8.1) 568 (18.2) 60 (15.6) 628 (16.3) former 698 (34.7) 447 (27.7) 1000 (32.0) 145 (37.7) 1145 (29.5) current 800 (39.8) 933 (64.1) 1553 (49.8) 180 (46.8) 1733 (54.2) Smoking status (%) 710 (47.5) 1906 (61.1) 186 (48.3) 2092 (61.5)
former 698 (34.7) 447 (27.7) 1000 (32.0) 145 (37.7) 1145 (29.5) current 800 (39.8) 933 (64.1) 1553 (49.8) 180 (46.8) 1733 (54.2) Smoking status (%) 710 (47.5) 1906 (61.1) 186 (48.3) 2092 (61.5)
current 800 (39.8) 933 (64.1) 1553 (49.8) 180 (46.8) 1733 (54.2) Smoking status (%)
Smoking status (%) never 1382 (68.8) 710 (47.5) 1906 (61.1) 186 (48.3) 2092 (61.5)
never 1382 (68.8) 710 (47.5) 1906 (61.1) 186 (48.3) 2092 (61.5)
former 320 (15.9) 391 (26.2) 589 (18.9) 122 (31.7) 711 (16.2)
current 308 (15.3) 394 (26.4) 625 (20.0) 77 (20.0) 702 (22.3)
BMI 30.02 (6.90) 28.81 (5.34) 28.99 (6.09) 33.24 (5.97) 29.43 (6.21)
OSA status = OSA,
AHI ≥15 (%) 141 (7.0) 244 (16.3) 0 (0.0) 385 (100.0) 385 (10.2)
AHI (3%
desaturation) 3.64 (7.52) 8.01 (14.93) 2.60 (3.43) 33.80 (20.62) 5.79 (11.97)
Overnight
Hypoxemia (>=5%
side (5.7) Side (5.7) (0.2) (21.4) (2.0) (27.6)
$(ADA)^{\dagger} = Yes (\%)$ 376 (18.7) 283 (18.9) 527 (16.9) 132 (34.3) 659 (15.3)
status \ddagger = Yes (%) 642 (31.9) 458 (30.6) 869 (27.8) 231 (60.0) 1100 (25.8)
Triglycerides
(mg/dL) 115.91 (71.29) 144.00 (99.29) 124.97 (83.48) 171.88 (107.33) 129.77 (87.38)
HDL (mg/dL) 52.51 (12.73) 45.18 (11.90) 49.44 (13.03) 44.06 (10.11) 48.89 (12.86)
LDL (mg/dL) 119.63 (35.66) 122.36 (35.61) 120.43 (35.72) 125.75 (34.77) 120.97 (35.66)
Fasting glucose
(mg/dL) 99.99 (32.62) 104.72 (34.52) 100.92 (31.83) 114.64 (44.85) 102.33 (33.65)
Fasting insulin 197.84 200.34 199.60 199.07
(mU/L) (147.49) (142.42) (145.42) 194.39 (141.28) (145.00)
HOMA-IR 3.39 (3.72) 3.48 (5.41) 3.17 (3.26) 5.77 (10.53) 3.43 (4.63)
Total cholesterol
(mg/dL) 195.40 (41.67) 196.06 (42.86) 194.82 (42.38) 203.65 (40.35) 195.72 (42.26)
Systolic blood
Diastolic blood pressure (mmhg) 71.02 (10.53) 74.32 (10.92) 71.87 (10.60) 79.49 (10.61) 72.65 (10.85)

^{*} Means and percentages were weighted using sampling weights to provides estimates of the

279 HCHS/SOL target population characteristics.

280	† Baseline diabetes are based on American Diabetes Association definition (Diabetes Care 2010;33:S62-
281	69), defined as fasting glucose >=100 mg/dL, or post-OGTT glucose >=140 mg/dL or A1C>=5.7%, or use
282	of anti-diabetic medication.
283	\ddagger Baseline hypertension is defined as systolic or diastolic BP greater than or equal to 140/90
284	respectively, or current use of antihypertensive medications.
285	
286	Metabolite associations with OSA and AHI
287	Table 2 shows the odds ratios corresponding to 7 metabolites associated (FDR $P < 0.05$) with
288	OSA in HCHS/SOL adjusted for age, sex, BMI, study site/center, race/ethnicity). Figure 2A and
289	S3 Tables show the lifestyle adjusted model and comorbidity adjusted model results. Among
290	the 7 mapped metabolites in MESA, 4 metabolite associations had one sided p-values < 0.05 –
291	glutamate, phenylalanine, linoleoyl-linoleoyl-glycerol (18:2/18:2), and oleoyl-linoeleoyl-glycerol
292	(18:1/18:2), all of which were associated with increased risks for OSA (Figure 2B). These
293	associations also had FDR p-value<0.05 in MESA. No metabolite was associated with AHI after
294	multiple testing correction in the HCHS/SOL (Supplemental Figure 2). Also, no metabolite
295	associations were detected at the FDR< 0.05 level in minimally adjusted sex-stratified analyses

in HCHS/SOL.

297 Table 2. Single metabolite associations with FDR-adjusted p-value <0.05 in the discovery step

	Super-				HCHS/SOL						
Biochemical	pathway	Sub-pathway	HMDB ID	OR	Unadj-p†	FDR p	Platform	OR	Unadj-p†	1-sided p	1-sided FDR p
glutamate	Amino Acid	Glutamate	HMDB00148	1.33							
		Metabolism			1.36E-04	0.014	Amide-neg	1.16	1.11E-02	0.006	0.019
phenylalanine	Amino Acid	Phenylalanine	HMDB00159	1.23							
		Metabolism			1.63E-03	0.049	HIL-pos	1.17	3.55E-03	0.002	0.014
linoleoyl-linoleoyl-glycerol	Lipid	Diacylglycerol	HMDB07248	1.25							
(18:2/18:2) [1]*					8.27E-04	0.040	HIL-pos	1.11	3.47E-02	0.017	0.030
oleoyl-linoleoyl-glycerol	Lipid	Diacylglycerol	HMDB07219	1.29							
(18:1/18:2) [1]					8.90E-05	0.014	HIL-pos	1.13	1.51E-02	0.008	0.019
1-palmitoleoylglycerol (16:1)*	Lipid	Monoacylglycerol	HMDB11565	1.21	1.15E-03	0.040	C8-pos	0.92	9.96E-02	0.950	0.950
1-stearoyl-2-linoleoyl-GPE	Lipid	Phosphatidyletha	HMDB08994	1.25							
(18:0/18:2)*		nolamine (PE)			9.89E-04	0.040	HIL-pos	1.03	5.37E-01	0.269	0.314
1-stearoyl-2-oleoyl-GPE	Lipid	Phosphatidyletha	HMDB08993	1.28							
(18:0/18:1)		nolamine (PE)			2.77E-04	0.019	C8-pos	1.04	4.49E-01	0.225	0.314

²⁹⁸ * Metabolite with * indicates they were identified based on accurate mass data, retention time and mass spectrometry but not reference

299 standards. Therefore, the verification is not as robust as metabolites without *.

300 [†] All results were adjusted for age, gender, BMI, study center, and Hispanic/Latino background in HCHS/SOL, and adjusted for age, sex, BMI,

301 study site (site WFU and UCLA are combined due to low cell count), and race in MESA. Unadj-*p* is the abbreviations of raw *p* before the FDR

302 correction. 1-sided p-values reflect the required of the same direction of associations in the discovery and validation datasets for concluding

303 replication.



Figure 2. Heatmap showing estimated odds ratios of metabolites with significant FDR-adjusted p-value for OSA in HCHS/SOL and in MESA

* indicates FDR *p*<0.05. In HCHS/SOL: Model 1 adjusted for age, gender, center, background, and bmi. Model 2 adjusted for age, gender, center, background, bmi, alcohol use, smoking status, physical activity and diet (AHEI 2010). Model 3 adjusted for age, gender, center, background, bmi, alcohol use, smoking status, physical activity, diet, T2DM, hypertension, fasting glucose, fasting insulin, HOMA_IR, HDL, LDL, total cholesterol, triglycerides, systolic blood pressure and diastolic blood pressure. In MESA: Model 1 adjusted for age, gender, BMI, study site (site WFU and UCLA are combined due to low cell count), and race. Model 2 adjusted for age, gender, BMI, study site, race, alcohol use, smoking status. Model 3 adjusted for age, gender, BMI, study site, race, alcohol use, smoking status, hypertension indicator, fasting glucose, HDL, LDL, cholesterol, triglycerides, systolic blood pressure and diastolic blood pressure.

306

LASSO regression for joint selection and estimation of metabolite associations with OSA and AHI in HCHS/SOL

- 309 We used a LASSO regression to select a set of metabolites that jointly associated with sleep
- apnea traits in the HCHS/SOL. Among the 14 metabolites identified for OSA by LASSO (Figure 3),
- 311 there were one carbohydrate, one peptide, three amino acids, three lipids, three nucleotides,
- 312 and three cofactors and vitamins, among which biliverdin and serine were unique to the OSA
- 313 metabolite index while the rest were shared between the OSA and AHI metabolite indices. 41
- metabolites were identified for AHI (Supplemental Figure 3), among which 29 metabolites were
- 315 unique to AHI metabolite index. Metabolites identified by sex-specific LASSO are provided in
- the supplemental materials (Supplemental Figures 4-7).

318



Figure 3: Coefficients for metabolites selected by LASSO (OSA model) in HCHS/SOL.

Blue: coefficient<0; Red: coefficient>0. Definition of abbreviations: OSA = moderate to severe obstructive sleep apnea (AHI≥15), LASSO = least absolute shrinkage and selection operator.

- 320 Metabolite indices associations with OSA and AHI in HCHS/SOL and in
- 321 independent validation in MESA
- 322 We constructed OSA and AHI metabolite indices in both HCHS/SOL and MESA based on the
- 323 weights from the LASSO regressions conducted in HCHS/SOL. Table 3 provides overall and sex-
- 324 stratified results. As expected by construction, the metabolite indices were associated with
- their phenotypes in HCHS/SOL (OSA metabolite index OR: 1.50; 95% CI 1.30-1.74; P < 0.001; AHI

326	metabolite index beta =2.12 per 1 SD of the index, 95% CI 1.43-2.81; <i>P</i> < 0.001) after
327	adjustment for demographic covariates (i.e., age, sex, BMI, study center, and Hispanic/Latino
328	background); the associations persisted after additional adjustment of lifestyle (i.e., alcohol
329	usage, smoking status, physical activity and diet) and comorbidity (i.e., diabetes, hypertension,
330	fasting glucose, fasting insulin, HOMA-IR, HDL, LDL, total cholesterol, triglycerides, systolic
331	blood pressure, diastolic blood pressure) covariates (OSA metabolite index OR: 1.50; 95% CI
332	1.21-1.85; <i>P</i> < 0.001; AHI metabolite index beta =1.73 per 1 SD of the index, 95% CI 0.96-2.50;
333	P<0.001). In the validation dataset, the OSA metabolite index was also associated with an
334	increased odds ratio for OSA (OR: 1.41; 95% CI 1.13-1.77; <i>P</i> = 0.003) (Table 3) when adjusted for
335	demographic (i.e., age, sex, BMI, study site, and race) covariates and remained similar when
336	adjusted for lifestyle (i.e., alcohol usage and smoking status) and comorbidity (i.e.,
337	hypertension, fasting glucose, HDL, LDL, cholesterol, triglycerides, systolic blood pressure and
338	diastolic blood pressure) covariates (OR: 1.55; 95% Cl 1.10-2.20; <i>P</i> = 0.013). When compared
339	with the lowest quartile of the OSA metabolite index, the top quartile showed more than two-
340	fold increase in risk for OSA [OR: 2.53; 95% CI (1.37-4.70); $P = 0.003$] in the primary model and
341	remained significant when adjusted for lifestyle and comorbidity covariates [OR: 2.63; 95% CI
342	(1.14-6.14); <i>P</i> = 0.024] (see Figure 3 and Supplemental Figure 3). AHI metabolite index
343	associations had higher p-values in MESA, compared to OSA metabolite index associations
344	(Table 3). AHI metabolite index was only replicated in women, adjusted for demographic,
345	lifestyle, and comorbidity covariates in MESA. Notably, both OSA metabolite index and AHI
346	metabolite index associations with their phenotypes were stronger when evaluated in women
347	compared to the overall sample, in both HCHS/SOL and MESA.

OSA			HCHS/	SOL					MESA	٨		
	Bot	h	Mal	e	Fema	le	Both		Male		Fema	le
Predictors	OR*	р	OR	р	OR	р	OR	р	OR	р	OR	р
Model 1 [†]												
OSA-Met Index	1.50	<0.001	1.41	<0.001	1.78	<0.001	1.41	0.003	1.17	0.403	1.48	0.009
	[1.30-1.74]		[1.17 - 1.70]		[1.47-2.14]		[1.13–1.77]		[0.81-1.72]		[1.11-2.00]	
Male-specific			1.67	<0.001					1.20	0.369		
OSA-Met Index			[1.39-2.00]						[0.81-1.79]			
Female-specific					2.12	<0.001					1.34	0.082
OSA-Met Index					[1.70-2.66]						[0.97-1.86]	
Model 2‡												
OSA-Met Index	1.53	<0.001	1.44	< 0.001	1.86	<0.001	1.39	0.004	1.15	0.476	1.46	0.013
	[1.33-1.77]		[1.20-1.72]		[1.52-2.27]		[1.11 - 1.76]		[0.78-1.69]		[1.09-1.98]	
Male-specific			1.71	<0.001					1.17	0.433		
OSA-Met Index			[1.43-2.05]						[0.79-1.75]			
Female-specific					2.19	<0.001					1.39	0.053
OSA-Met Index					[1.71-2.79]						[1.00-1.94]	
Model 3§												
OSA-Met Index	1.50	<0.001	1.43	0.009	1.89	<0.001	1.55	0.013	1.30	0.365	1.71	0.026
	[1.21-1.85]		[1.09-1.88]		[1.35-2.64]		[1.10-2.20]		[0.74-2.30]		[1.07-2.78]	
Male-specific			1.71	<0.001					1.13	0.600		
OSA-Met Index			[1.39-2.09]						[0.71-1.82]			
Female-specific					2.17	<0.001					1.41	0.094
OSA-Met Index					[1.54-3.04]						[0.95–2.11]	
AHI			HCHS/	SOL					MESA	١		
	Bot	h	Mal	e	Fema	ale	Both		Male		Fema	le
Predictors	Estimates	р	Estimates	р	Estimates	р	Estimates	р	Estimates	р	Estimates	р
Model 1 [†]												
AHI-Met Index	2.12	<0.001	2.39	<0.001	1.47	<0.001	1.45	0.083	-1.59	0.254	3.38	0.001
	[1.43-2.81]		[1.21-3.58]		[1.00-1.94]		[-0.19_3.08]		[-4.33–1.15]		[1.42-5.33]	
Male-specific			3.54	<0.001					-1.99	0.628		
AHI-Met Index			[2.04-5.03]						[-10.11-6.12]			

Table 3. Estimated associations between OSA and AHI metabolite indices and their respective phenotypes, in HCHS/SOL and MESA

Female-specific					1.70	<0.001					2.75	0.013
AHI-Met Index					[0.98-2.43]						[0.57-4.93]	
Model 2‡												
AHI-Met Index	2.12	<0.001	2.41	<0.001	1.49	<0.001	1.42	0.089	-1.55	0.269	3.25	0.001
	[1.41-2.83]		[1.22-3.61]		[1.01-1.96]		[-0.22-3.06]		[-4.32–1.21]		[1.30-5.21]	
Male-specific			3.62	<0.001					-2.10	0.612		
AHI-Met Index			[2.10-5.14]						[-10.25-6.05]			
Female-specific					1.69	<0.001					2.80	0.012
AHI-Met Index					[0.97-2.42]						[0.63–4.98]	
Model 3§												
AHI-Met Index	1.73	<0.001	2.14	0.002	1.11	<0.001	1.20	0.181	-0.96	0.527	2.65	0.014
	[0.96–2.50]		[0.79–3.48]		[0.64-1.58]		[-0.56-2.96]		[-3.96–2.03]		[0.54-4.76]	
Male-specific			3.34	<0.001					-2.45	0.581		
AHI-Met Index			[1.65-5.02]						[-11.21-6.31]			
Female-specific					1.05	0.001					2.09	0.092
AHI-Met Index					[0.43-1.67]						[-0.34–4.52]	

* per 1 STD increase in metabolite index (Met Index).

[†] Model 1 adjusted for age, gender, BMI, study center, and Hispanic/Latino background in HCHS/SOL, and adjusted for age, gender, BMI, study site (site WFU and UCLA are combined due to low cell count), and race in MESA.

+ Model 2 adjusted for all covariates in model 1, in HCHS/SOL model 2 additionally adjusted for alcohol usage, smoking status, physical activity and diet; in MESA, model 2 additionally adjusted for alcohol usage and smoking status.

[§] Model 3 adjusted for all covariates in model 2, in HCHS/SOL, model 3 additionally adjusted for diabetes, hypertension, fasting glucose, fasting insulin, HOMA-IR, HDL, LDL, total cholesterol, triglycerides, systolic blood pressure, diastolic blood pressure; in MESA, model 3 additionally adjusted for hypertension indicator, fasting glucose, HDL, LDL, cholesterol, triglycerides, systolic blood pressure and diastolic blood pressure.

1

Results from secondary analysis of a sex specific metabolite indices are also provided in Table 3.
Only the female-specific AHI metabolite index replicated in MESA in model 1 and 2, but its
association with AHI in women was weaker than that of the AHI metabolite index trained on
the full HCHS/SOL sample, both in terms of p-value and of estimated effect size.

6

7 Discussion

In this paper, we leveraged metabolomics data from two large, diverse community-based 8 cohorts to derive the first metabolite index for moderate to severe OSA, as well as to identify 9 10 individual metabolites associated with this disorder. We studied 219 metabolites and their associations with OSA and AHI in the HCHS/SOL using two methods: (1) analysis of individual 11 metabolites, and (2) LASSO to identify a subset of metabolites that jointly predict OSA or AHI. 12 Then, we studied the associations in an independent validation study, MESA. We used the 13 results from LASSO to derive an OSA and AHI metabolite indices. In MESA, the OSA metabolite 14 index was significantly associated with moderate to severe OSA; e.g., individuals in the highest 15 16 quartile for OSA metabolite index had a more than 2-fold increased odds of moderate to severe 17 OSA- both in the derivation sample and in an independent sample that varied by ancestry, age, and OSA prevalence, with findings that persisted after adjusting for multiple lifestyle and health 18 19 covariates. In contrast, when modeling AHI as a continuous measure of sleep apnea, weaker 20 associations were observed, except for the top quartiles among females. In the association

analysis of individual metabolites, seven metabolites were associated with OSA in HCHS/SOL (FDR p < 0.05), of which four associations replicated in MESA.

23

24	We implemented two approaches to study the metabolomic correlates of sleep apnea
25	phenotypes: LASSO and individual-metabolite regression analysis. These approaches serve
26	different purposes: single metabolite regression highlights individual metabolites associated
27	with sleep apnea phenotypes without adjustment to other metabolites, while LASSO estimates
28	the combined effect of multiple metabolites. A metabolite identified as associated with sleep
29	apnea phenotypes individually may not be selected by the LASSO analysis (e.g., if a different
30	metabolite correlated to it was selected by LASSO). Thus, it is not surprising that two of the
31	replicated metabolites identified in single metabolite analysis were not selected by LASSO.
32	Similarly, a specific metabolite may be selected by LASSO, but not by individual metabolite
33	analysis due to adjustment for multiple testing, which is not done in LASSO analysis. The OSA
34	metabolite index, constructed based on the LASSO results, is a single index using multiple blood
35	biomarkers which together reflect the biochemical differences in the blood of individuals with
36	and without OSA. The OSA metabolite index also showed stronger association with OSA than
37	any single metabolite, in both the discovery and validation study, consistent with the influence
38	of multiple metabolites in OSA pathophysiology (see Table 3, S3 Table). While future work is
39	needed to study whether the metabolite index can be used in the clinic for OSA screening or
40	clinical management of OSA patients, it is clearly useful from a statistical and epidemiological
41	standpoints, as analysis based on the metabolite index had evidently higher statistical power
42	than analyses testing single metabolite associations. Therefore, it may also enable additional

43 studies of the pathophysiology of OSA and its relationship with other cardiometabolic44 conditions.

45

46	Four metabolites were replicated in the single metabolite regression: glutamate, oleoyl-
47	linoleoyl-glycerol (18:1/18:2) (DAG(36:3)), linoleoyl-linoleoyl-glycerol (18:2/18:2) (DAG(36:4))
48	and phenylalanine, among which glutamate and phenylalanine remained positively associated
49	with OSA after adjusting for lifestyle and comorbidities in addition to basic demographics. Both
50	metabolites have some previous evidence linking them to OSA or other sleep disorders, as well
51	as cardiometabolic diseases, and suggest that elevations in glutamate and phenylalanine can be
52	investigated as biomarkers for adverse outcomes in patients with OSA. High plasma glutamate
53	has been associated with total and visceral adiposity, dyslipidemia and insulin resistance (27),
54	as well as increased risks for incident cardiovascular disease (28), type 2 diabetes (29), and
55	subclinical atherosclerosis (30), independent of established cardiovascular risk factors. The
56	positive association between glutamate and OSA observed in our study may suggest a shared
57	metabolomic profile for OSA and other cardiometabolic phenotypes. Previous studies in rats
58	animals and human showed that more frequent sleep apneas led to increased level of
59	glutamate in brain (31–33). Glutamate is the major excitatory neurotransmitter in the brain,
60	and modulates brain energy metabolism and neuronal synaptic plasticity. Although the blood-
61	brain barrier prevents plasma glutamate to freely permeate into the central nervous system
62	(34), when glutamate increases in the brain, the brain-to-blood glutamate efflux also increases,
63	as suggested by the correlation between the peripheral glutamate and the central nerve system

glutamate levels (35). These findings support further research addressing the roles of peripheral
and central glutamate in the pathophysiology of OSA.

66

67	Phenylalanine is an essential aromatic amino acid that plays a key role in the biosynthesis of
68	other amino acids, including the neurotransmitters, dopamine, and norepinephrine. Studies
69	have shown that plasma phenylalanine level can be elevated due to inflammation (36,37), and
70	inflammation is a common finding in OSA (38). One mechanism for the increased levels of
71	phenylalanine may be through chronic hypoxia, which has been reported to increase both
72	systemic and cerebral delivery of phenylalanine (39). This is in line with our evidence:
73	peripheral phenylalanine was elevated among individuals with moderate to severe OSA
74	patients (S3 Table). A prior lab-based study that measured a few metabolites over the course of
75	sleep reported that phenylalanine levels decreased less overnight among patients with OSA
76	compared to controls (40). Phenylalanine levels were also reported to be elevated after sleep
77	restriction (41). The downstream effects of phenylalanine have been studied more widely in
78	other chronic conditions, with reports of associations with elevated pro-inflammatory
79	cytokines, suppressed immunity and increased mortality among heart failure patients (42);
80	more rapid telomere shortening consistent with accelerated aging (43). Recent studies reported
81	elevations of phenylalanine associated with adverse COPD outcomes (44), which was
82	postulated to reflect muscle breakdown and respiratory muscle insufficiency (45). Elevated
83	plasma phenylalanine was shown to be a strong predictor for cardiovascular risk (46) and a
84	biomarker, mediator and potentially therapeutic target for pulmonary hypertension (47).
85	Further research on the association of OSA and phenylalanine may further identify the roles of

hypoxia, inflammation, and muscle function in the pathophysiology of OSA and cardiometabolicconditions.

88

89	Our study has also shown that increased plasma levels of two diacylglycerols (DAGs): DAG(36:3)
90	and DAG(36:4) were associated with moderate to severe OSA. Altered lipids metabolism is
91	often observed among OSA patients (48–50); specifically, intermittent hypoxemia can
92	stimulate lipolysis, increasing free fatty acid levels (51). Abnormalities in lipid metabolism may
93	result in liver and skeletal muscle fat deposition, exacerbating OSA through inflammatory or
94	muscle-related pathways (52). Therefore, the associations with these diacylglycerols may
95	reflect mechanisms by which OSA related hypoxemia alters fatty acid metabolism. These
96	associations, however, did not replicate in the validation study once adjusted for comorbidities,
97	suggesting that the associations might be confounded by cardiometabolic conditions that often
98	accompany OSA.
99	
100	Estimated OSA associations, in both LASSO and single metabolite analysis, were generally
101	stronger than AHI associations. Potential reasons are the variability of AHI and the potential
102	non-linear metabolomic associations with AHI. Notably, non-linearity (i.e., a threshold effect)

was previously shown for AHI association with hypoxemia and sympathetic nervous systemactivation burden (53).

106 Sex differences have been increasingly reported among OSA patients (17). Population-based studies have shown that the overall OSA prevalence is higher among men than women (54), 107 while metabolic syndrome and cardiovascular conditions are more strongly associated with OSA 108 109 among female patients compared to males (55,56). Indeed, when assessing the metabolite indices developed in both sexes and tested for their associations with OSA and AHI, we 110 observed stronger associations among women than men in the MESA validation dataset (Table 111 3). However, compared to the metabolite indices developed in combined sex strata, sex-specific 112 metabolite indices had weaker associations with the OSA/AHI in the validation data set (weaker 113 114 effect size estimates and higher p-value), which may be the result of more misclassification when using a smaller dataset for discovery. 115 In addition to pointing to novel individual metabolites that play a role in OSA, our metabolite 116 117 indices also showed moderately strong associations with OSA in an external sample, despite the marked differences in race/ethnicity, age, and OSA prevalence compared to the discovery 118 sample. This supports the overall generalizability of the metabolite index across diverse 119 populations. Nonetheless, the utility of a 2-fold increased risk of OSA among individuals in the 120 highest metabolite index quartile in helping to screen or triage patients for more 121 comprehensive testing will need to be formally evaluated, potentially combining metabolite 122 data with other information, such as OSA-related symptoms, to improve screening. 123 124

prior studies (57), includes a high proportion of ethnic/racial minorities who have been under-

125

A strength of our study is that our population-based sample is more than 10-fold larger than

127	represented in research but are at increased for adverse health outcomes, and is more
128	representative of samples in the general population who remain include large numbers of
129	undiagnosed individuals. We used rigorous statistical methods, adjusted for a large number of
130	lifestyle and health covariates, and were able to replicate the main findings despite large
131	differences in our discovery and validation populations, which suggests relatively strong
132	associations and generalizability of the metabolite associations with OSA.

133

There are several limitations in this study. The temporal relationship between the blood sample 134 collection and sleep test was concurrent in HCHS/SOL and up to one year apart in MESA, 135 allowing for cross-sectional associations, but limiting our ability to discern causal pathways. 136 137 Although over 1000 metabolites were quantified in both populations, less than 300 metabolites were matched between the two platforms (after quality control only 219 distinct metabolites 138 were mapped). We limited our study to only the matched metabolites to allow for replication 139 testing, which strengthens the results and conclusions. MESA metabolomic profiling was 140 conducted using three complementary platforms measuring several broad classes of small 141 142 molecules therefore multiple chemical compounds from MESA were mapped to the same 143 metabolite in the HCHS/SOL. We chose a single feature to map to any HCHS/SOL metabolite based on a set of rules related presence of redundant ions, data missingness and skewness. In 144 the future, other more optimal approaches may be proposed and studied. Some associations 145 failed to replicate in MESA, potentially due to heterogeneity in different populations and low 146 147 power in MESA, which had a small sample size. Finally, the definitions of AHI differed slightly in the two studies: while the 3% oxyhemoglobin desaturation criterion applied to hypopneas only 148

in MESA, due to differences in the recording montage, a 3% desaturation criterion was appliedfor all respiratory events in HCHS/SOL.

151

152	In summary, we used two large datasets of population-based multi-ethnic cohort studies to
153	study metabolomics associations with OSA. We developed an metabolite index that replicated
154	across datasets, and had statistically significant association with OSA even after adjustment to
155	cardiometabolic comorbidities. In future work we will study the possibility of developing an
156	OSA screening tool based on this metabolite index. Four metabolites also replicated in an
157	independent data set, of which one was previously implicated in OSA, and two were previously
158	connected to sleep disorders. Collectively, our findings support the utility of metabolomic
159	profiling to generate metabolite indices of sleep apnea in racially diverse populations, and to
160	OSA's pathophysiology.

162 Acknowledgement

- 163 The authors thank the staff and participants of HCHS/SOL and MESA for their important
- 164 contributions. We gratefully acknowledge the studies and participants who provided biological
- 165 samples and data for TOPMed.

166

167 Data availability statement

168 MESA and HCHS/SOL data are available through application to dbGaP according to the study

- 169 specific accessions. MESA phenotypes are available in: phs000209, and HCHS/SOL
- 170 phenotypes: phs000810. HCHS/SOL metabolomics data are available via data use agreement
- 171 with the HCHS/SOL Data Coordinating Center at the University of North Carolina at Chapel Hill,
- 172 see collaborators website: <u>https://sites.cscc.unc.edu/hchs/</u>.

173

174 Funding

- 175 The research was partially supported by NIH NHLBI R35 HL135818. Support for metabolomics
- data was graciously provided by the JLH Foundation (Houston, Texas). The Hispanic
- 177 Community Health Study/Study of Latinos was carried out as a collaborative study supported by
- 178 contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North
- 179 Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein College of
- 180 Medicine (N01-HC65235), Northwestern University (N01-HC65236), and San Diego State
- 181 University (N01-HC65237). The following Institutes/Centers/Offices contribute to the HCHS/SOL
- through a transfer of funds to the NHLBI: National Center on Minority Health and Health
- 183 Disparities, the National Institute of Deafness and Other Communications Disorders, the
- 184 National Institute of Dental and Craniofacial Research, the National Institute of Diabetes and

185 Digestive and Kidney Diseases, the National Institute of Neurological Disorders and Stroke, and 186 the Office of Dietary Supplements. The authors thank the staff and participants of HCHS/SOL for their important contributions. MESA and the MESA SHARe project are conducted and 187 supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA 188 189 investigators. Support for MESA is provided by contracts HHSN268201500003I, N01-HC-190 95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, 191 192 UL1-TR-001079, UL1-TR-001420. MESA Family is conducted and supported by the National 193 Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support is 194 provided by grants and contracts R01HL071051, R01HL071205, R01HL071250, R01HL071251, 195 R01HL071258, R01HL071259 and by the National Center for Research Resources, Grant UL1RR033176. The MESA Sleep Ancillary study was funded by NIH-NHLBI R01HL098433. 196 The provision of genotyping data was supported in part by the National Center for Advancing 197 198 Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and 199 Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the 200 Southern California Diabetes Endocrinology Research Center. Molecular data for the Trans-201 Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung 202 and Blood Institute (NHLBI).). Metabolomics for "NHLBI TOPMed: Multi-Ethnic Study of Atherosclerosis (MESA)" (phs001416) was performed at Broad Institute and Beth Israel 203 204 Metabolomics Platform (HHSN268201600038I). Core support including centralized genomic read mapping and genotype calling, along with variant guality metrics and filtering were 205 provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract 206 HHSN268201800002I). Core support including phenotype harmonization, data management, 207 208 sample-identity QC, and general program coordination were provided by the TOPMed Data 209 Coordinating Center (R01HL-120393; U01HL-120393; contract HHSN268201800001).

210 Reference

Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, et al. Sleep apnea and
 cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation
 Scientific Statement from the American Heart Association Council for High Blood Pressure Research
 Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On
 Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National
 Center on Sleep Disorders Research (National Institutes of Health). Circulation. 2008 Sep
 2;118(10):1080–1111.

Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep disordered breathing in adults. Am J Epidemiol. 2013 May 1;177(9):1006–1014.

Kapur V, Strohl KP, Redline S, Iber C, O'Connor G, Nieto J. Underdiagnosis of sleep apnea
 syndrome in U.S. communities. Sleep Breath. 2002 Jun;6(2):49–54.

Lastra AC, Attarian HP. The persistent gender bias in the diagnosis of obstructive sleep apnea.
 Gender and the Genome. 2018 Apr;2(2):43–48.

Redline S, Sotres-Alvarez D, Loredo J, Hall M, Patel SR, Ramos A, et al. Sleep-disordered
 breathing in Hispanic/Latino individuals of diverse backgrounds. The Hispanic Community Health
 Study/Study of Latinos. Am J Respir Crit Care Med. 2014 Feb 1;189(3):335–344.

Chen X, Wang R, Zee P, Lutsey PL, Javaheri S, Alcántara C, et al. Racial/Ethnic Differences in
 Sleep Disturbances: The Multi-Ethnic Study of Atherosclerosis (MESA). Sleep. 2015 Jun 1;38(6):877–888.

7. Redline S. Genetics of obstructive sleep apnea. Principles and practice of sleep medicine.
Elsevier; 2011. p. 1183–1193.

Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep disordered breathing and hypertension. N Engl J Med. 2000 May 11;342(19):1378–1384.

Kasai T, Floras JS, Bradley TD. Sleep apnea and cardiovascular disease: a bidirectional
 relationship. Circulation. 2012 Sep 18;126(12):1495–1510.

Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, et al. Sleep apnea and
daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J
Clin Endocrinol Metab. 2000 Mar;85(3):1151–1158.

Heilbrunn ES, Ssentongo P, Chinchilli VM, Oh J, Ssentongo AE. Sudden death in individuals with
 obstructive sleep apnoea: a systematic review and meta-analysis. BMJ Open Respir Res. 2021 Jun;8(1).

240 12. Idle JR, Gonzalez FJ. Metabolomics. Cell Metab. 2007 Nov;6(5):348–351.

241 13. Ussher JR, Elmariah S, Gerszten RE, Dyck JRB. The Emerging Role of Metabolomics

in the Diagnosis and Prognosis of Cardiovascular Disease. J Am Coll Cardiol. 2016 Dec 27;68(25):2850–
2870.

24414.Hunter WG, Kelly JP, McGarrah RW, Khouri MG, Craig D, Haynes C, et al. Metabolomic profiling245identifies novel circulating biomarkers of mitochondrial dysfunction differentially elevated in heart

failure with preserved versus reduced ejection fraction: evidence for shared metabolic impairments inclinical heart failure. J Am Heart Assoc. 2016 Jul 29;5(8).

248 15. Ferrarini A, Rupérez FJ, Erazo M, Martínez MP, Villar-Álvarez F, Peces-Barba G, et al.

Fingerprinting-based metabolomic approach with LC-MS to sleep apnea and hypopnea syndrome: a pilot study. Electrophoresis. 2013 Oct;34(19):2873–2881.

25116.Engeli S, Blüher M, Jumpertz R, Wiesner T, Wirtz H, Bosse-Henck A, et al. Circulating anandamide252and blood pressure in patients with obstructive sleep apnea. J Hypertens. 2012 Dec;30(12):2345–2351.

Won CHJ, Reid M, Sofer T, Azarbarzin A, Purcell S, White D, et al. Sex differences in obstructive
sleep apnea phenotypes, the multi-ethnic study of atherosclerosis. Sleep. 2020 May 12;43(5).

18. Lavange LM, Kalsbeek WD, Sorlie PD, Avilés-Santa LM, Kaplan RC, Barnhart J, et al. Sample
design and cohort selection in the Hispanic Community Health Study/Study of Latinos. Ann Epidemiol.
2010 Aug;20(8):642–649.

19. Westbrook PR, Levendowski DJ, Cvetinovic M, Zavora T, Velimirovic V, Henninger D, et al.
Description and validation of the apnea risk evaluation system: a novel method to diagnose sleep apneahypopnea in the home. Chest. 2005 Oct;128(4):2166–2175.

20. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh
performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for
the identification and relative quantification of the small-molecule complement of biological systems.
Anal Chem. 2009 Aug 15;81(16):6656–6667.

265 21. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-Ethnic Study of
266 Atherosclerosis: objectives and design. Am J Epidemiol. 2002 Nov 1;156(9):871–881.

Paynter NP, Balasubramanian R, Giulianini F, Wang DD, Tinker LF, Gopal S, et al. Metabolic
 predictors of incident coronary heart disease in women. Circulation. 2018 Feb 20;137(8):841–853.

269 23. Lumley T. survey: analysis of complex survey samples [Internet]. 2020 [cited 2021 Nov 18].
 270 Available from: https://cran.r-project.org/web/packages/survey/index.html

271 24. Benjamini Y. Discovering the false discovery rate. J Royal Statistical Soc B. 2010 Aug 5;72(4):405–
272 416.

273 25. Sofer T, Heller R, Bogomolov M, Avery CL, Graff M, North KE, et al. A powerful statistical
274 framework for generalization testing in GWAS, with application to the HCHS/SOL. Genet Epidemiol. 2017
275 Apr;41(3):251–258.

276 26. Friedman J, Hastie T, Tibshirani R, Narasimhan B, Tay K, Simon N. Package glmnet. J Stat Softw.
277 2010 Feb 21;33(1).

278 27. Cheng S, Rhee EP, Larson MG, Lewis GD, McCabe EL, Shen D, et al. Metabolite profiling identifies
279 pathways associated with metabolic risk in humans. Circulation. 2012 May 8;125(18):2222–2231.

280 28. Zheng Y, Hu FB, Ruiz-Canela M, Clish CB, Dennis C, Salas-Salvado J, et al. Metabolites of

281 glutamate metabolism are associated with incident cardiovascular events in the PREDIMED prevención

con dieta mediterránea (PREDIMED) trial. J Am Heart Assoc. 2016 Sep 15;5(9).

283 29. Liu X, Zheng Y, Guasch-Ferré M, Ruiz-Canela M, Toledo E, Clish C, et al. High plasma glutamate
284 and low glutamine-to-glutamate ratio are associated with type 2 diabetes: Case-cohort study within the
285 PREDIMED trial. Nutr Metab Cardiovasc Dis. 2019 Oct;29(10):1040–1049.

286 30. Lehn-Stefan A, Peter A, Machann J, Schick F, Randrianarisoa E, Heni M, et al. Elevated Circulating
287 Glutamate Is Associated With Subclinical Atherosclerosis Independently of Established Risk Markers: A
288 Cross-Sectional Study. J Clin Endocrinol Metab. 2021 Jan 23;106(2):e982–e989.

289 31. Fung SJ, Xi M-C, Zhang J-H, Sampogna S, Yamuy J, Morales FR, et al. Apnea promotes glutamate-290 induced excitotoxicity in hippocampal neurons. Brain Res. 2007 Nov 7;1179:42–50.

32. Macey PM, Sarma MK, Nagarajan R, Aysola R, Siegel JM, Harper RM, et al. Obstructive sleep
apnea is associated with low GABA and high glutamate in the insular cortex. J Sleep Res. 2016
Aug;25(4):390–394.

29433.Macey PM, Sarma MK, Prasad JP, Ogren JA, Aysola R, Harper RM, et al. Obstructive sleep apnea295is associated with altered midbrain chemical concentrations. Neuroscience. 2017 Nov 5;363:76–86.

296 34. Hawkins RA. The blood-brain barrier and glutamate. Am J Clin Nutr. 2009 Sep;90(3):867S–874S.

297 35. Alfredsson G, Wiesel FA, Tylec A. Relationships between glutamate and monoamine metabolites
298 in cerebrospinal fluid and serum in healthy volunteers. Biol Psychiatry. 1988 Apr 1;23(7):689–697.

36. Murr C, Grammer TB, Meinitzer A, Kleber ME, März W, Fuchs D. Immune activation and
inflammation in patients with cardiovascular disease are associated with higher phenylalanine to
tyrosine ratios: the ludwigshafen risk and cardiovascular health study. J Amino Acids. 2014 Feb
10;2014:783730.

303 37. Strasser B, Sperner-Unterweger B, Fuchs D, Gostner JM. Mechanisms of Inflammation 304 Associated Depression: Immune Influences on Tryptophan and Phenylalanine Metabolisms. Current
 305 topics in behavioral neurosciences. 2017;31:95–115.

306 38. Huang T, Goodman M, Li X, Sands SA, Li J, Stampfer MJ, et al. C-reactive Protein and Risk of OSA
307 in Four US Cohorts. Chest. 2021 Jun;159(6):2439–2448.

308 39. Dahl RH, Berg RMG, Taudorf S, Bailey DM, Lundby C, Christensen M, et al. Transcerebral
309 exchange kinetics of large neutral amino acids during acute inspiratory hypoxia in humans. Scand J Clin
310 Lab Invest. 2019 Dec;79(8):595–600.

40. Kiens O, Taalberg E, Ivanova V, Veeväli K, Laurits T, Tamm R, et al. The effect of obstructive sleep
apnea on peripheral blood amino acid and biogenic amine metabolome at multiple time points
overnight. Sci Rep. 2021 May 24;11(1):10811.

314 41. Bell LN, Kilkus JM, Booth JN, Bromley LE, Imperial JG, Penev PD. Effects of sleep restriction on
315 the human plasma metabolome. Physiol Behav. 2013 Oct 2;122:25–31.

42. Chen W-S, Wang C-H, Cheng C-W, Liu M-H, Chu C-M, Wu H-P, et al. Elevated plasma

phenylalanine predicts mortality in critical patients with heart failure. ESC Heart Fail. 2020
Oct;7(5):2884–2893.

43. Eriksson JG, Guzzardi M-A, Iozzo P, Kajantie E, Kautiainen H, Salonen MK. Higher serum
phenylalanine concentration is associated with more rapid telomere shortening in men. Am J Clin Nutr.
2017 Jan;105(1):144–150.

44. Ubhi BK, Riley JH, Shaw PA, Lomas DA, Tal-Singer R, MacNee W, et al. Metabolic profiling detects
biomarkers of protein degradation in COPD patients. Eur Respir J. 2012 Aug;40(2):345–355.

45. Kuo W-K, Liu Y-C, Chu C-M, Hua C-C, Huang C-Y, Liu M-H, et al. Amino Acid-Based Metabolic
Indexes Identify Patients With Chronic Obstructive Pulmonary Disease And Further Discriminates
Patients In Advanced BODE Stages. Int J Chron Obstruct Pulmon Dis. 2019 Sep 30;14:2257–2266.

46. Würtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, et al. Metabolite
profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation.
2015 Mar 3;131(9):774–785.

47. Tan R, Li J, Liu F, Liao P, Ruiz M, Dupuis J, et al. Phenylalanine induces pulmonary hypertension
through calcium-sensing receptor activation. Am J Physiol Lung Cell Mol Physiol. 2020 Dec
1;319(6):L1010–L1020.

48. Lebkuchen A, Carvalho VM, Venturini G, Salgueiro JS, Freitas LS, Dellavance A, et al.

Metabolomic and lipidomic profile in men with obstructive sleep apnoea: implications for diagnosis and
 biomarkers of cardiovascular risk. Sci Rep. 2018 Jul 26;8(1):11270.

49. Geovanini GR, Wang R, Weng J, Jenny NS, Shea S, Allison M, et al. Association between
Obstructive Sleep Apnea and Cardiovascular Risk Factors: Variation by Age, Sex, and Race. The MultiEthnic Study of Atherosclerosis. Annals of the American Thoracic Society. 2018;15(8):970–977.

So. Nadeem R, Singh M, Nida M, Waheed I, Khan A, Ahmed S, et al. Effect of obstructive sleep apnea
hypopnea syndrome on lipid profile: a meta-regression analysis. J Clin Sleep Med. 2014 May
15;10(5):475-489.

S1. Chopra S, Rathore A, Younas H, Pham LV, Gu C, Beselman A, et al. Obstructive sleep apnea
dynamically increases nocturnal plasma free fatty acids, glucose, and cortisol during sleep. J Clin
Endocrinol Metab. 2017 Sep 1;102(9):3172–3181.

345 52. Bonsignore MR, McNicholas WT, Montserrat JM, Eckel J. Adipose tissue in obesity and
346 obstructive sleep apnoea. Eur Respir J. 2012 Mar;39(3):746–767.

347 53. Alvarez D, Hornero R, Abásolo D, del Campo F, Zamarrón C. Nonlinear characteristics of blood
348 oxygen saturation from nocturnal oximetry for obstructive sleep apnoea detection. Physiol Meas. 2006
349 Apr;27(4):399–412.

Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC, et al. Prevalence of
obstructive sleep apnea in the general population: A systematic review. Sleep Med Rev. 2017
Aug;34:70–81.

Fietze I, Laharnar N, Obst A, Ewert R, Felix SB, Garcia C, et al. Prevalence and association analysis
of obstructive sleep apnea with gender and age differences - Results of SHIP-Trend. J Sleep Res. 2019
Oct;28(5):e12770.

S6. Chaudhary P, Goyal A, Goel SK, Kumar A, Chaudhary S, Kirti Keshri S, et al. Women with OSA
have higher chances of having metabolic syndrome than men: effect of gender on syndrome Z in cross
sectional study. Sleep Med. 2021 Mar;79:83–87.

- 359 57. Zhang X, Wang S, Xu H, Yi H, Guan J, Yin S. Metabolomics and microbiome profiling as
 360 biomarkers in obstructive sleep apnoea: a comprehensive review. Eur Respir Rev. 2021 Jun 30;30(160).
- 361
- 362 Supporting information
- 363
- 364 S1 Table. Mapping between MESA and HCHS/SOL Metabolomics Platform. The mapping was carried
- 365 out before any quality control steps (e.g. assessment of missingness, etc.). 294 compounds in MESA
- 366 were mapped to 231 metabolites in HCHS/SOL. 60 redundant features in MESA were dropped based on
- 367 the principles described in the methods section. After discarding 12 metabolites with high
- 368 missingness(>=75%) in HCHS/SOL, 209 metabolites with low missingness (<25%) were imputed and 10
- 369 metabolites with medium missingness (25-75%) were dichotomized in the HCHS/SOL metabolomics
- 370 platform. We applied the same QC steps to the corresponding metabolites in MESA, i.e., discarded,
- imputed, and dichotomized, the same metabolites in MESA as in HCHS/SOL.
- 372 S2 Table. Characteristics of the analytic sample from the MESA study population. * Baseline
- 373 hypertension is defined as systolic blood pressure (SBP) > 130 mmHg, diastolic blood pressure (DBP) > 80
- 374 mmHg or any history of antihypertensive medication intake.

375 **S3 Table. Single metabolite associations with FDR-adjusted p-value <0.05 in HCHS/SOL and MESA.**

- 376 Model 1 adjusted for age, gender, BMI, study center, and Hispanic/Latino background in HCHS/SOL, and
- adjusted for age, gender, BMI, study site (site WFU and UCLA are combined due to low cell count), and
- 378 race in MESA. Model 2 adjusted for all covariates in model 1, in HCHS/SOL model 2 additionally adjusted
- 379 for alcohol usage, smoking status, physical activity and diet; in MESA, model 2 additionally adjusted for
- alcohol usage and smoking status. Model 3 adjusted for all covariates in model 2, in HCHS/SOL, model 3

additionally adjusted for diabetes, hypertension, fasting glucose, fasting insulin, HOMA-IR, HDL, LDL,
total cholesterol, triglycerides, systolic blood pressure, diastolic blood pressure; in MESA, model 3
additionally adjusted for hypertension indicator, fasting glucose, HDL, LDL, cholesterol, triglycerides,
systolic blood pressure and diastolic blood pressure. Metabolite with * indicates they were identified
based on accurate mass data, retention time and mass spectrometry but not reference standards.
Therefore, the verification is not as robust as metabolites without *.

387 S4 Table. Estimated associations between OSA and AHI metabolite indices and their respective

388 **phenotypes in quartiles, in HCHS/SOL and MESA.** * per 1 STD increase in metabolite index. Model 1

adjusted for age, gender, BMI, study center, and Hispanic/Latino background in HCHS/SOL, and adjusted

for age, gender, BMI, study site (site WFU and UCLA are combined due to low cell count), and race in

391 MESA. Model 2 adjusted for all covariates in model 1, in HCHS/SOL model 2 additionally adjusted for

alcohol usage, smoking status, physical activity and diet; in MESA, model 2 additionally adjusted for

393 alcohol usage and smoking status. Model 3 adjusted for all covariates in model 2, in HCHS/SOL, model 3

additionally adjusted for diabetes, hypertension, fasting glucose, fasting insulin, HOMA-IR, HDL, LDL,

total cholesterol, triglycerides, systolic blood pressure, diastolic blood pressure; in MESA, model 3

additionally adjusted for hypertension indicator, fasting glucose, HDL, LDL, cholesterol, triglycerides,

397 systolic blood pressure and diastolic blood pressure.